Currus Biologics is utilising its proprietary BEAT technology to develop CAR-T cell therapies for the treatment of solid tumour cancers, traditionally difficult to treat with current CAR-T cell therapies. Currus Biologics’ proprietary Bispecific Engagers of Antigen Presenting Cells and T cells (BEA...See more
Headquarter Australia |
Countries of operation Australia |
Year founded 2021 (3 years) |
Funding status Series A |
Company type SME |
Head of Manufacturing
Drug Development Manager
Senior Scientist